[摘要] 非酒精性脂肪性肝病(NAFLD)病理生理基础主要是胰岛素抵抗和氧化应激，而缓解胰岛素抵抗，减少氧化应激、降血脂和护肝等是治疗NAFLD主要策略。临床试验证实罗格列酮，二甲双胍，维生素E和C，阿托伐他汀等治疗可不同程度地缓解转氨酶异常、脂肪变性、炎症和肝纤维化。一些药物前景不错，但还缺乏充分有力的随机对照试验，所以目前还没有任何一种药物推荐专用治疗NAFLD。

    [关键词] 非酒精性脂肪性肝病；药物治疗：罗格列酮

    [中图分类号] R575[文献标识码]A [文章编号]1673-7210(2008)04(a)-019-03

    Advances in pharmacological therapy of nonalcoholic fatty liver disease abroad

    HAN Chun-sheng, DING Xiu-fang

    (Department of Endocrinology, Third Affiliated Hospital of Qiqihaer Medical College, Qiqihaer 161000,China)

    [Abstract] Principal foundation of pathology and physiology in nonalcoholic fatty liver disease(NAFLD) is insulin resistance and oxidative stress,.and therapy strategy of NAFLD mainly includes: lessening insulin resistance, reducing oxidative stress, lipid-modulating and liver-protecting. Clinical trials confirm different level remission of transaminase disorders, steatosis, inflammation and liver fibrosis with treatment of rosiglitazone, metformin, atorvastatin Vitamins E and C etc.The development of many drugs lacks of adequately powered, randomized, controlled trials, so that it is currently difficult to make evidence-based recommendations on pharmacological treatment in NAFLD. ......